Earnings ·
Exelixis reports Q3 revenue of $658.7M and diluted EPS of $0.85
EXELExelixis, Inc.
Exelixis reported third-quarter 2026 total revenues of $658.7 million, up from $597.8 million in the prior-year period, driven by a 11.4% increase in net product revenues to $604.9 million. GAAP diluted earnings per share reached $0.85, compared to $0.69 in the same quarter last year, while non-GAAP diluted EPS was $0.94 versus $0.78. The company also announced a settlement with Azurity Pharmaceuticals granting a license for its proposed generic cabozantinib product effective December 1, 2030, and provided an updated PDUFA target date of March 3, 2027, for the FDA review of zanzalintinib. Exelixis operates as an oncology company developing and commercializing small molecule medicines.